Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
Recruiting · NCT07413835 · Registry updated 2026-03-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG) | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Not applicable | 2026-03-18 | NCT07413835 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shenzhen MagicRNA Biotechnology Co., Ltd | 4 |
| The Affiliated Hospital of Xuzhou Medical University | 68 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou | China | 30 |